Physician profile
Brian Christopher Smith
NPI 1598144917
$2,980.80
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $181 · 2020: $16.61 · 2021: $12.59 · 2022: $113 · 2023: $855 · 2024: $1,803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,650 · Food and Beverage: $918 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,650.00 |
| Food and Beverage | $917.60 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $1,650.00 | 2024 | Brukinsa |
| Daiichi Sankyo INC. | $271.20 | 2021-2024 | Enhertu |
| Janssen Biotech, INC. | $197.63 | 2020-2023 | Darzalex, Tecvayli |
| Novartis Pharmaceuticals Corporation | $93.70 | 2022-2023 | |
| Seagen INC. | $85.91 | 2023 | Tukysa |
| Pharmacyclics LLC, An Abbvie Company | $83.89 | 2019-2023 | Epkinly |
| Celgene Corporation | $72.42 | 2023 | Pomalyst, Reblozyl, Opdualag |
| Mirati Therapeutics, INC. | $60.82 | 2023 | Krazati |
| Merck Sharp & Dohme LLC | $60.45 | 2022-2023 | Keytruda, Lynparza |
| Stemline Therapeutics INC. | $57.82 | 2023-2024 | Orserdu |
| Jazz Pharmaceuticals INC. | $56.01 | 2019 | |
| Astellas Pharma US INC | $51.48 | 2019 | |
| Karyopharm Therapeutics INC. | $38.44 | 2023 | Xpovio |
| Genzyme Corporation | $33.39 | 2019-2023 | |
| Taiho Oncology, INC. | $29.97 | 2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $26.07 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.75 | 2024 | Fruzaqla |
| Lilly USA, LLC | $19.00 | 2023 | Jaypirca |
| Aveo Pharmaceuticals, INC. | $15.91 | 2023 | Fotivda |
| Array Biopharma INC | $14.27 | 2023 | Braftovi, Lorbrena, Xalkori |
| Sobi, INC | $14.20 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $13.90 | 2022 | |
| Amgen INC. | $11.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.